Bavarian Nordic (BAVA)

242.1
+2.6(+1.09%)
  • Volume:
    824,987
  • Bid/Ask:
    0.0/0.0
  • Day's Range:
    236.0 - 246.3
  • Type:Equity
  • Market:Denmark
  • ISIN:DK0015998017
  • S/N:70472935

BAVA Overview

Prev. Close
239.5
Day's Range
236-246.3
Revenue
1.9B
Open
240
52 wk Range
115.2-369.3
EPS
-7.48
Volume
824,987
Market Cap
17.03B
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
871,248
P/E Ratio
-
Beta
1.32
1-Year Change
-6.63%
Shares Outstanding
70,332,942
Next Earnings Date
23 Aug 2022
What is your sentiment on Bavarian Nordic?
or
Market is currently closed. Voting is open during market hours.

Bavarian Nordic Company Profile

Bavarian Nordic Company Profile

Employees
759
Market
Denmark

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellNeutralBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong BuyStrong BuySell
SummaryStrong SellSellStrong BuyStrong BuyNeutral
  • By at close above 247,2
    0